Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INO-3106, INO-9012 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort I | EXPERIMENTAL | 3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9); |
| Cohort II | EXPERIMENTAL | 6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9 |
| Name | Type | Description |
|---|---|---|
| INO-3106, INO-9012 | BIOLOGICAL | - |
Inclusion Criteria: * Signed and dated written Ethics Committee approved informed consent * Age ≥18 years * Histologically documented HPV-6 positive aerodigestive invasive malignancy (mucosal squamous cell head and neck cancer or lung cancer) who have completed therapies such as radiation/chemoradi...
INO-3106 is an investigational immunotherapy being studied for the treatment of aerodigestive precancerous lesions and malignancies associated with HPV-6. It is currently in clinical development and has not been approved by the FDA.
INO-3106 is a monoclonal antibody that targets HPV-6, a virus associated with aerodigestive precancerous lesions and malignancies. By targeting this virus, the therapy aims to treat conditions caused by HPV-6 infection.
INO-3106 is developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol INO.
INO-3106 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy.
INO-3106 has been studied in a Phase 1 clinical trial with the identifier NCT02241369, titled 'Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies'. This trial was completed in the United States with 3 participants.
INO-3106 and INO-9012 are both being developed by Inovio Pharmaceuticals, Inc. They are listed together as a combination therapy for the treatment of aerodigestive precancerous lesions and malignancies.